Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study

Annals of the Rheumatic Diseases

Volumn 74, Issue 2, 2015, Pages 389-395

  Tanaka, Yoshiya ^a   Hirata, Shintaro ^a   Kubo, Satoshi ^a   Fukuyo, Shunsuke ^a   Hanami, Kentaro ^a   Sawamukai, Norifumi ^a   Nakano, Kazuhisa ^a   Nakayamada, Shingo ^a   Yamaoka, Kunihiro ^a   Sawamura, Fusae ^b   Saito, Kazuyoshi ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b ABBVIE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CYCLOOXYGENASE 2 INHIBITOR; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; STROMELYSIN; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL STUDY; CONTROLLED STUDY; DAS28; DISEASE ACTIVITY; DISEASE DURATION; DRUG EFFICACY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE; HEALTH ASSESSMENT QUESTIONNAIRE DISABILITY INDEX; HUMAN; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PROGNOSIS; RATING SCALE; RECEIVER OPERATING CHARACTERISTIC; REMISSION; RHEUMATOID ARTHRITIS; SIMPLIFIED DISEASE ACTIVITY INDEX; STATISTICAL MODEL; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; ARTHRITIS, RHEUMATOID; CLINICAL TRIAL; MIDDLE AGED;

ADALIMUMAB; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; AREA UNDER CURVE; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; MALE; MIDDLE AGED; REMISSION INDUCTION; ROC CURVE;

EID: 84921295252     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-204016     Document Type: Article

References (22)

1. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet 2001;358:903-11.
2. Pope RM. Apoptosis as a therapeutic tool in rheumatoid arthritis. Nat Rev Immunol 2002;2:527-35.
3. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001;344:907-16.
4. Aaltonen KJ, Virkki LM, Malmivaara A, et al. Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PLoS One 2012;7:e30275.
5. Clark DA. Do anti-TNF-α drugs increase cancer risk in rheumatoid arthritis patients? Inflammopharmacology 2013;21:125-7.
6. Wong AK, Kerkoutian S, Said J, et al. Risk of lymphoma in patients receiving antitumor necrosis factor therapy: a meta-analysis of published randomized controlled studies. Clin Rheumatol 2012;31:631-6.
7. Kaymakcalan Z, Sakorafas P, Bose S, et al. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin Immunol 2009;131:308-16.
8. Arora T, Padaki R, Liu L, et al. Differences in binding and effector functions between classes of TNF antagonists. Cytokine 2009;45:124-31.
9. Mitoma H, Horiuchi T, Tsukamoto H, et al. Mechanisms for cytotoxic effects of anti-TNF agents on transmembrane TNF-expressing cells: comparison among infliximab, etanercept and adalimumab. Arthritis Rheum 2008;58:1248-57.
10. Quinn MA, Conaghan PG, O'Connor PJ, et al. Very early treatment with inf iximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005;52:27-35.
11. Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different strategies in patients with early rheumatoid arthritis (the BeSt study): arandomizedcontrolledtrial. Arthritis Rheum 2005;52:3381-90.
12. Detert J, Bastian H, Listing J, et al. Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study. Ann Rheum Dis 2013;72:844-50.
13. Smolen JS, Emery P, Fleischmann R, et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomized controlled OPTIMA trial. Lancet 2013. Epub ahead of print. doi:pii: S0140-6736(13)61751-1. 10.1016/S0140-6736(13)61751-1.
14. Tanaka Y, Takeuchi T, Mimori T, et al. RRR study investigators. Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. Ann Rheum Dis 2010;69:1286-91.
15. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
16. Koike R, Takeuchi T, Eguchi K, Miyasaka N; Japan College of Rheumatology. Mod Rheumatol 2007;17:451-8.
17. Japan College of Rheumatology, Official Guidelines for the Use of Anti-TNF Agents for Rheumatoid Arthritis (in Japanese). 2012. http://www.ryumachi-jp.com/info/guideline TNF 120704.html
18. Prevoo ML, van 't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective Discontinuation of Adalimumab in rheumatoid arthritis (HONOR study): longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
19. Tanaka Y. Intensive treatment and treatment holiday of TNF-inhibitors in rheumatoid arthritis. Curr Opin Rheumatol 2012;24:319-26.
20. Fries JF, Spitz P, Kraines RG, et al. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45.
21. van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 2000;27:261-3.
22. Takeuchi T, Tanaka Y, Kaneko Y, et al. Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study). Mod Rheumatol 2012;22:327-38.